Recombinant Human CD82 protein (rFc Tag) (HPLC verified)

Species

Human

Purity

>90 %, SDS-PAGE
>90 %, SEC-HPLC

Tag

rFc Tag

Activity

not tested

Cat no : Eg1749



Product Information

Purity >90 %, SDS-PAGE
>90 %, SEC-HPLC
Endotoxin <0.1 EU/μg protein, LAL method
Activity
Not tested
Expression HEK293-derived Human CD82 protein Gly111-Leu228 (Accession# P27701-1) with a rabbit IgG Fc tag at the C-terminus.
GeneID 3732
Accession P27701-1
PredictedSize 39.8 kDa
SDS-PAGE 43-60 kDa, reducing (R) conditions
Formulation Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
Reconstitution Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
Storage Conditions
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

CD82 is a membrane glycoprotein and belongs to the tetraspanin superfamily, many of which are implicated in the regulation of cell motility, morphology, fusion, signaling, fertilization, and differentiation CD82 was originally identified as a suppressor of metastasis located on human chromosome 11p11.2 in prostate carcinoma. The majority of evidence indicates that CD82 expression is downregulated or abolished in a variety of malignant tumors. CD82 is present at high levels in human monocyte and macrophage lineages and in various epithelial cells in the prostate, lung, pancreas and many other tissues. In epithelial cells, CD82 is implicated in diverse biological processes such as cell adhesion, migration, apoptosis and morphogenesis. The tetraspanin CD82 is a potent suppressor of tumor metastasis and regulates several processes including signal transduction, cell adhesion, motility, and aggregation. CD82 is a key regulator of TLR9 trafficking and signaling. CD82 expressed by macrophages and dendritic cells associates with class II major histocompatibility complex (MHC) and other components of the antigen-processing and presentation pathway.

References:

1.Feng J, et al. (2015). Cancer Metastasis Rev. 34(4):619-33. 2.Khan NS, et al. (2019). FASEB J. 33(11):12500-12514. 3.Kropshofer H, et al. (2002). Nat Immunol. 3(1):61-8. 4.Jones EL, et al. (2016). J Immunol. 196(3):978-87.